Search results for "Clinical endpoint"

showing 9 items of 339 documents

One week of levofloxacin plus dexamethasone eye drops for cataract surgery: an innovative and rational therapeutic strategy

2020

Background: Cataract surgery is the most common operation performed worldwide. A fixed topical corticosteroid-antibiotic combination is usually prescribed in clinical practice for 2 or more weeks to treat post surgical inflammation and prevent infection. However, this protracted schedule may increase the incidence of corticosteroid-related adverse events and notably promote antibiotic resistance. Methods: This International, multicentre, randomized, blinded-assessor, parallel-group clinical study evaluated the non-inferiority of 1-week levofloxacin/dexamethasone eye drops, followed by 1-week dexamethasone alone, vs. 2-week gold-standard tobramycin/dexamethasone (one drop QID for all schedul…

medicine.medical_specialtymedicine.medical_treatmentLevofloxacinArticleDexamethasoneCataract03 medical and health sciences0302 clinical medicineEndophthalmitisPharmacotherapyPostoperative ComplicationsLevofloxacinInternal medicinemedicineTobramycinClinical endpointHumansEndophthalmitis Cataract Intracameral cefuroximeAdverse effectDexamethasoneEndophthalmitisbusiness.industryCataract surgeryIntracameral cefuroximemedicine.diseasenot applicableAnti-Bacterial AgentsOphthalmologyItalySpain030221 ophthalmology & optometryOphthalmic Solutionsbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability …

2012

Background Although significant efforts have been made to improve ST-segment elevation myocardial infarction (STEMI) outcomes by reducing symptom-onset-to-reperfusion times, strategies to decrease the clinical impact of ischemic reperfusion injury have demonstrated limited success. Bendavia, an intravenously administered mitochondrial targeting peptide, has been shown to reduce myocardial infarct size and attenuate coronary no-reflow in experimental modelswhen given before reperfusion. Design The EMBRACE STEMI study is a phase 2a, randomized, double-blind, placebo-controlled trial enrolling 300 patients with a first-time anterior STEMI and an occluded proximal or mid–left anterior descendin…

medicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionPlacebo-controlled studyMyocardial Reperfusion InjuryPlaceboClinical Trials Phase II as TopicInternal medicinemedicineClinical endpointHumansInfusions Intra-ArterialST segmentcardiovascular diseasesMyocardial infarctionRandomized Controlled Trials as Topicbusiness.industryPatient SelectionPercutaneous coronary interventionmedicine.diseaseResearch DesignConventional PCICardiologyNo-Reflow PhenomenonStentsCardiology and Cardiovascular MedicinebusinessOligopeptidesReperfusion injuryAmerican Heart Journal
researchProduct

Multicenter experience with the antegrade fenestration and reentry technique for chronic total occlusion recanalization

2020

Objectives We aimed to evaluate the efficacy and safety of antegrade fenestration and reentry (AFR) for chronic total occlusion (CTO) recanalization in a multicenter registry. Background Adoption of antegrade dissection/reentry (ADR) for CTO recanalization has been limited, and novel ADR techniques are needed. Methods AFR involves the balloon-induced creation of multiple fenestrations between the false and true lumen. A targeted true lumen reentry is subsequently achieved with a low tip-load polymer-jacketed guidewire. Following the initial description and dissemination of AFR, patients undergoing AFR-based CTO recanalization at nine centers were included in the present registry. Study endp…

medicine.medical_specialtyreentrymedicine.medical_treatmentLumen (anatomy)Dissection (medical)030204 cardiovascular system & hematologyCoronary AngiographyTotal occlusion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionmedicineClinical endpointHumansRadiology Nuclear Medicine and imagingRegistries030212 general & internal medicinechronic total occlusionbusiness.industryPercutaneous coronary interventionGeneral MedicineReentrymedicine.diseaseSurgeryTreatment OutcomedissectionCoronary OcclusionChronic DiseaseCardiology and Cardiovascular MedicinebusinessFenestration
researchProduct

Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support: Study Protocol for a Single Center, Sin…

2021

Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is the rescue treatment proposed to patients with refractory cardiogenic shock. The VA-ECMO implantation promotes inflammation and ischemia-reperfusion injuries through the VA-ECMO flow, causing digestive mucosa barrier disrupture and inducing translocation of bacterial wall components—Lipopolysaccharides (LPS) with further inflammation and circulatory impairment. LPS is a well-studied surrogate indicator of bacterial translocation. Oxiris membrane is a promising and well-tolerated device that can specifically remove LPS. The main study aim is to compare the LPS elimination capacity of Oxiris membrane vs. a non-absorban…

medicine.medical_treatmentcontinuous renal replacement therapyheart failureoxirisContext (language use)InflammationCardiovascular Medicineartificial membranelaw.inventionStudy ProtocolRandomized controlled triallawmedicineClinical endpointExtracorporeal membrane oxygenationDiseases of the circulatory (Cardiovascular) systemRenal replacement therapycytokines/bloodbusiness.industryCardiogenic shockcardiogenic shockextracorporeal membrane oxygenationmedicine.diseasesurgical procedures operativeendotoxin/bloodRC666-701AnesthesiaHeart failuremedicine.symptomCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Open-label ODYSSEY APPRISE study: Interim data from the first 843 participants

2018

Background PCSK9 inhibitors (PCSK9i) have been recommended by the ESC/EAS Task Force in very high risk subjects with ASCVD and those with heterozygous familial hypercholesterolemia (HeFH) with persistent high LDL-C levels despite maximally tolerated LLT. Purpose ODYSSEY APPRISE (NCT02476006) is the first study to assess efficacy and safety at Week (W) 12 of the PCSK9i alirocumab (ALI) in a real-life setting prior to commercial availability. Methods APPRISE was an open-label, single-arm study, conducted in 16 European countries and Canada. Subjects with inadequately controlled lipid levels despite maximally tolerated LLT were included. Based on physician's judgment, participants received eit…

myalgiamedicine.medical_specialtyErythemabusiness.industryFamilial hypercholesterolemia030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineTolerabilityInternal medicineClinical endpointmedicineBack painmedicine.symptomCardiology and Cardiovascular MedicineAdverse effectbusiness030217 neurology & neurosurgeryAlirocumabArchives of Cardiovascular Diseases Supplements
researchProduct

Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy

2021

Optimal antithrombotic therapy after percutaneous coronary intervention (PCI) in patients on oral anticoagulants (OAC) remains a clinical conundrum. In fact, combining an OAC with dual antiplatelet therapy (triple antithrombotic therapy, TAT) increases the risk of bleeding. Clopidogrel is the only thienopyridine recommended in TAT patients. Whether its response plays a relevant role in this setting remains uncertain. We aimed to evaluate the level of platelet reactivity inhibition (PRI) achieved by oral TAT in Acute Coronary Syndrome (ACS) patients undergoing PCI and its relationship with outcomes. We performed a multicenter prospective observational study and assessed PRI by vasodilator-st…

platelet reactivityAcute coronary syndromemedicine.medical_specialtyThienopyridinetriple antithrombotic therapymedicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematologyLoading doseArticleacute coronary syndromeVASP index03 medical and health sciences0302 clinical medicineInternal medicineAntithromboticClinical endpointMedicinecardiovascular diseases030212 general & internal medicineclopidogrelbusiness.industrylcsh:RPercutaneous coronary interventionGeneral Medicinemedicine.diseaseClopidogrelConventional PCICardiologybusinessmedicine.drugJournal of Clinical Medicine
researchProduct

Pressure support ventilation + sigh in acute hypoxemic respiratory failure patients: Study protocol for a pilot randomized controlled trial, the PROT…

2018

Background Adding cyclic short sustained inflations (sigh) to assisted ventilation yields optimizes lung recruitment, decreases heterogeneity and reduces inspiratory effort in patients with acute hypoxemic respiratory failure (AHRF). These findings suggest that adding sigh to pressure support ventilation (PSV) might decrease the risk of lung injury, shorten weaning and improve clinical outcomes. Thus, we conceived a pilot trial to test the feasibility of adding sigh to PSV (the PROTECTION study). Methods PROTECTION is an international randomized controlled trial that will be conducted in 23 intensive care units (ICUs). Patients with AHRF who have been intubated from 24 h to 7 days and under…

procedurePressure supportTime Factorsgenetic structuresbreathingmedicine.medical_treatmentMedicine (miscellaneous)Pilot Projects[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractintensive care unitlaw.inventionPositive-Pressure RespirationStudy Protocol0302 clinical medicineMechanical ventilationRandomized controlled triallawtime factorClinical endpointpatient safetyMulticenter Studies as TopicPharmacology (medical)030212 general & internal medicinerandomized controlled trial (topic)Intervention study; Mechanical ventilation; Positive-pressure ventilation; Pressure support; Recruitment; Sigh; Ventilator-induced lung injury; Weaning; Feasibility Studies; Humans; Hypoxia; Intubation Intratracheal; Lung; Multicenter Studies as Topic; Pilot Projects; Positive-Pressure Respiration; Recovery of Function; Respiratory Insufficiency; Time Factors; Treatment Outcome; Randomized Controlled Trials as Topic; Medicine (miscellaneous); Pharmacology (medical)HypoxiaLungpathophysiologyendotracheal intubationRandomized Controlled Trials as TopicVentilator-induced lung injurylcsh:R5-920Intervention studyadultpilot studyfeasibility studytreatment outcome Feasibility Studie3. Good healthTreatment OutcomeAnesthesiapositive end expiratory pressureBreathingmulticenter study (topic)oxygenationRecruitmentlcsh:Medicine (General)Respiratory Insufficiencyrespiratory tract intubationcirculatory and respiratory physiologyHumanextubationPressure support ventilationWeaningLung injuryArticleSpontaneous breathing trialNO03 medical and health sciencesIntensive care[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]medicineIntubation IntratrachealHumanscontrolled studyPilot ProjectSightreatment failureMechanical ventilationhypoxemiapressure support ventilationtreatment durationbusiness.industrylung inflationrespiratory failureconvalescenceRecovery of Functionmajor clinical studymortalitywater acute respiratory failurehospital dischargeIntratracheal030228 respiratory systemrandomized controlled trialFeasibility StudiesbusinessPositive-pressure ventilationIntubationclinical protocol
researchProduct

Mid-term and late results of endovascular treatment for symptomatic carotid artery stenosis under proximal protection

2021

Introduction: Although filters are still preferred during carotid stenting, proximal protection systems (PPS) are increasingly used during these procedures. PPS seem to be safer than distal systems, especially in symptomatic patients, but evidence supporting their use is limited. Aim: This was a post hoc survey with 30-day mid-term and long-term follow up, which was aimed at assessment of the safety and efficacy of stenting of the internal carotid artery under PPS in symptomatic patients. Material and methods: We analysed the results of stenting in 120 symptomatic patients presenting with at least 60% stenosis. Patients were aged 67.9 ±9.8 years, and 12 patients were older than 80 years. An…

proximal protectionmedicine.medical_specialtyUrologymedicine.medical_treatmentstenting030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicinemedicine.arteryOcclusionClinical endpointMedicineStrokeEndarterectomyOriginal Paperbusiness.industryRGastroenterologyObstetrics and Gynecologymedicine.diseasestrokeSurgeryStenosisMedicinecarotid stenosisSurgeryInternal carotid arteryCarotid stentingmedicine.symptombusiness030217 neurology & neurosurgeryVideosurgery and Other Miniinvasive Techniques
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct